Rivastigmine for Alzheimer's disease

To browse Podcasts by topic, please visit the new Cochrane Summaries site here

The use of cholinesterase inhibitors in people with Alzheimer's disease has long been a focus of interest and concern. In this podcast, Jacqueline Birks, a researcher from Oxford, England, reports the results of an updated systematic review studying the benefits and harms of one of these agents, rivastigmine, including a novel mode of percutaneous administration.

This Podcast also available in: French

Play Now!

You are missing some Flash content that should appear here! Perhaps your browser cannot display it, or maybe it did not initialize correctly.

Download [mp3]  | Read Review
library
Updated on: June 20, 2011, 14:39

Copyright © The Cochrane Collaboration
Comments for improvement or correction are welcome.
Email: web@cochrane.org